First Patient Enters Extension Trial Testing Higher Temelimab Doses & How to Hold Space with MS

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses a news article about how the first patient who completed GeNeuro’s ProTEct-MS Phase 2 trial has entered the study's extension, which will test higher doses of temelimab.Also, Price reads the column by Jamie Hughes, A Life in Letters, “You Don’t Always Need to Fix It”.=================================== Are you interested in learning more about multiple sclerosis? If so, please visit: https://multiplesclerosisnewstoday.com/ =====================================To join in on conversations regarding multiple sclerosis, please visit:https://multiplesclerosisnewstoday.com/forums/